This document summarizes an application brief about using micro-ultrasound to study cancer angiogenesis. It discusses how micro-ultrasound allows researchers to non-invasively visualize 3D tumor volume, neoangiogenesis, and blood perfusion over time in small animal models. This helps researchers better understand cancer development and anti-angiogenic therapies. VisualSonics' micro-ultrasound systems provide high resolution real-time imaging of tumor growth and vascularity to help reduce the number of animals needed for research.
Breast cancer research in animal models has long been hindered by the lack of a fast, portable,
high resolution, research and animal focused imaging system that can visualize 2D tumor size, 3D
tumor volume, neoangiogenesis and blood perfusion in vivo, in real-time and most importantly,
non-invasively.
In order to ameliorate this problem, VisualSonics has introduced a revolutionary micro-ultrasound
system that allows researchers to collect a plethora of important data over the lifespan of animals,
thereby significantly reducing the number of animals needed.
Breast cancer research in animal models has long been hindered by the lack of a fast, portable, high resolution, research and animal focused imaging system that can visualize 2D tumor size, 3D tumor volume, neoangiogenesis and blood perfusion in vivo, in real-time and most importantly, non-invasively.
(December 2, 2021) The Bench to Bedside Series: Preclinical Cancer Research w...Scintica Instrumentation
Overview:
The goal of this webinar will be to provide a high-level overview of the various stages of preclinical cancer research and discuss the role that innovative instrumentation can play in moving science forward.
To better understand how to treat and control cancer, researchers start by investigating the basics – the cells, molecules, and genes that make up the human body. This type of study, which is often referred to as basic or discovery research, aims to understand the underlying mechanisms contributing to cancer growth and spread. This knowledge is an essential starting point for developing future diagnostic tests and treatment strategies.
After finding an innovative idea that works in cells, researchers need to take their studies to the next level by employing animal models that have similar biology to humans. Animal models have helped scientists make some of the most important cancer discoveries over the years. Furthermore, preclinical imaging technologies allow researchers to perform longitudinal animal studies that are noninvasive leaving the underlying biology intact so that one can track changes throughout the entire disease process.
It was previously thought that the journey from bench to bedside was unidirectional, starting with discovery research and moving towards clinical trials. However, in the last decade, it has become crucial for basic scientists and clinicians to work together towards finding innovative solutions that will positively impact patient care.
After attending this webinar, we hope you will have a better understanding of the preclinical workflow needed to push an idea from bench to bedside as well as some of the key equipment that is needed along the way.
This webinar series will be hosted by Drs. Katie Parkins and Tyler Lalonde, both of which have extensive experience in translational research areas including oncology, neuroscience, molecular imaging, and drug development.
In this webinar we will discuss the following topics:
• Introduction To Cancer Research
• What does “Bench to Bedside” mean?
• In vitro characterization
• Rapid throughput screening
• Quantitative tools
• Moving towards translation
Improvisation of Conventional Techniques: The Future of Oncology Researchasclepiuspdfs
Since the past 2 ½ months, the medical science has been experiencing a paradigm shift with the monumental effects of the ongoing global pandemics, irrespective of the geographical periphery, ethnicity, and races. However, within this global crisis, we might lose the focus on another deadly foe of humankind, taking millions of lives for the last few centuries, that is, none other than cancer. The scientific fraternity across the world has been thoroughly intervening in the various wings of cancer research to secure the best possible outcome. Off late, a cascade of improvised tools has been taken into consideration in cancer research. In this paper, two of the most innovative protocols have been discussed those might be the potential boom in future oncology research if the mentioned methods could be implemented with proper vigilance, realistic outcome, and off course patience.
WEBINAR: The Four Ws of Preclinical Small Animal Imaging; What, When, Where &...Scintica Instrumentation
We will begin this 3-part preclinical imaging learning mini-series with this 60-minute webinar in which we will highlight five important preclinical imaging modalities including optical imaging, high frequency ultrasound, MRI, PET/CT, and fluorescence in vivo endomicroscopy. We will give a brief technical overview of each modality and discuss how an image is acquired. We will then review the strengths and weaknesses of each technology and provide some insight on when to use one over the other by highlighting some example images acquired on preclinical systems offered by Scintica Instrumentation.
Topics discussed in this webinar include:
The need for preclinical imaging
Technical overview: Optical, High Frequency Ultrasound, MRI, PET/CT, and Fluorescence in vivo Endomicroscopy
When each modality should be used
Different types of preclinical imaging applications
Multiplex imaging
Breast cancer research in animal models has long been hindered by the lack of a fast, portable,
high resolution, research and animal focused imaging system that can visualize 2D tumor size, 3D
tumor volume, neoangiogenesis and blood perfusion in vivo, in real-time and most importantly,
non-invasively.
In order to ameliorate this problem, VisualSonics has introduced a revolutionary micro-ultrasound
system that allows researchers to collect a plethora of important data over the lifespan of animals,
thereby significantly reducing the number of animals needed.
Breast cancer research in animal models has long been hindered by the lack of a fast, portable, high resolution, research and animal focused imaging system that can visualize 2D tumor size, 3D tumor volume, neoangiogenesis and blood perfusion in vivo, in real-time and most importantly, non-invasively.
(December 2, 2021) The Bench to Bedside Series: Preclinical Cancer Research w...Scintica Instrumentation
Overview:
The goal of this webinar will be to provide a high-level overview of the various stages of preclinical cancer research and discuss the role that innovative instrumentation can play in moving science forward.
To better understand how to treat and control cancer, researchers start by investigating the basics – the cells, molecules, and genes that make up the human body. This type of study, which is often referred to as basic or discovery research, aims to understand the underlying mechanisms contributing to cancer growth and spread. This knowledge is an essential starting point for developing future diagnostic tests and treatment strategies.
After finding an innovative idea that works in cells, researchers need to take their studies to the next level by employing animal models that have similar biology to humans. Animal models have helped scientists make some of the most important cancer discoveries over the years. Furthermore, preclinical imaging technologies allow researchers to perform longitudinal animal studies that are noninvasive leaving the underlying biology intact so that one can track changes throughout the entire disease process.
It was previously thought that the journey from bench to bedside was unidirectional, starting with discovery research and moving towards clinical trials. However, in the last decade, it has become crucial for basic scientists and clinicians to work together towards finding innovative solutions that will positively impact patient care.
After attending this webinar, we hope you will have a better understanding of the preclinical workflow needed to push an idea from bench to bedside as well as some of the key equipment that is needed along the way.
This webinar series will be hosted by Drs. Katie Parkins and Tyler Lalonde, both of which have extensive experience in translational research areas including oncology, neuroscience, molecular imaging, and drug development.
In this webinar we will discuss the following topics:
• Introduction To Cancer Research
• What does “Bench to Bedside” mean?
• In vitro characterization
• Rapid throughput screening
• Quantitative tools
• Moving towards translation
Improvisation of Conventional Techniques: The Future of Oncology Researchasclepiuspdfs
Since the past 2 ½ months, the medical science has been experiencing a paradigm shift with the monumental effects of the ongoing global pandemics, irrespective of the geographical periphery, ethnicity, and races. However, within this global crisis, we might lose the focus on another deadly foe of humankind, taking millions of lives for the last few centuries, that is, none other than cancer. The scientific fraternity across the world has been thoroughly intervening in the various wings of cancer research to secure the best possible outcome. Off late, a cascade of improvised tools has been taken into consideration in cancer research. In this paper, two of the most innovative protocols have been discussed those might be the potential boom in future oncology research if the mentioned methods could be implemented with proper vigilance, realistic outcome, and off course patience.
WEBINAR: The Four Ws of Preclinical Small Animal Imaging; What, When, Where &...Scintica Instrumentation
We will begin this 3-part preclinical imaging learning mini-series with this 60-minute webinar in which we will highlight five important preclinical imaging modalities including optical imaging, high frequency ultrasound, MRI, PET/CT, and fluorescence in vivo endomicroscopy. We will give a brief technical overview of each modality and discuss how an image is acquired. We will then review the strengths and weaknesses of each technology and provide some insight on when to use one over the other by highlighting some example images acquired on preclinical systems offered by Scintica Instrumentation.
Topics discussed in this webinar include:
The need for preclinical imaging
Technical overview: Optical, High Frequency Ultrasound, MRI, PET/CT, and Fluorescence in vivo Endomicroscopy
When each modality should be used
Different types of preclinical imaging applications
Multiplex imaging
(October 12, 2021) Webinar: Clinical Field MRI As A Measurement Instrument fo...Scintica Instrumentation
Watch our webinar where Professor Marc-Andre Fortin presented about the 3D printing of hydrogels and hydrated substances that have been introduced in various fields of biomedical research including regenerative medicine, cosmetic surgery, orthopedics, and medical physics.
However, one of the main challenges faced by 3D printing and bioprinting is geometrical conformity. In this presentation, studies requiring hydrogel 3D printing in the fields of ophthalmology, regenerative medicine, and medical physics, were described. MRI scanning procedures were developed and optimized for these specific applications.
The presentation highlighted the potential role of MRI in the development of more accurate, more precise 3D-printed hydrogel objects.
Peter Hamilton on Next generation Imaging and Computer Vision in Pathology: p...Cirdan
Automated image analysis has had a long history but continues to grow with massive improvements in algorithms, speed, performance, and with emerging opportunities for high throughput tissue biomarker analysis and automated decision support for primary diagnostics. Of particular importance is the development of computer vision and image analysis for H&E stained samples. This talk will outline recent advances in automated tissue analysis for biomarker discovery and diagnostics and how adoption of digital pathology will drive the demand for quantitative imaging and decision support.
As an example, PathXL have developed TissueMark for the automated identification and analysis of tumour in lung, colon, breast and prostate cancer digital H&E slides. The conventional pathological estimation of % tumour nuclei in H&E samples shows gross variation between pathologists, undermining the quality of next generation sequencing, molecular testing and patient therapy and potential of false negative diagnoses. TissueMark uses a combination of pattern recognition, glandular analysis and nuclear segmentation to identify premaligant and invasive cancer patterns in H&E stained tissues and use this to assess tumour cell numbers and annotate samples for nucleic acid extraction and molecular profiling. Benchmark data was generated to validate TissueMark technology and showed concordance of automated data with manual counts, accelerating tumour markup and improving sample quality assessment. This represents an example of how automated imaging of tissue samples can be of immense value in quantitative tumour analysis for molecular diagnostics, thereby improving reliability in discovery and diagnostics.
This together with other examples in pathology research and practice will demonstrate that next generation tissue imaging technology in digital pathology could radically change how pathology is practiced.
Molecular imaging has revolutionized our perceptions of imaging. This high impact field is finding transformative applications in the understanding, detection, and treatment of nearly all diseases.
The field of molecular imaging is a an exciting fusion and integration of many different disciplines including molecular biology, chemistry and probe design, imaging technologies, visualization, and image analysis, that are focused on understanding, detecting, and treating oncological, neurological, cardiovascular, inflammatory, metabolic, and infectious diseases. Based on their strengths, different imaging modalities provide different but equally valuable information that can be integrated in advancing our understanding of these diseases.
As the era of ‘omics’ progresses towards personalized medicine, the field of molecular imaging is finding multiple uses in noninvasive characterization of the molecular features of diseases and their impact on function. In complex diseases such as cancer, with its tremendous genetic diversity, it is becoming increasingly important to develop molecularly-targeted treatment strategies that combine detection with treatment.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Manuel Salto-Tellez on Personalised medicine and the future of tissue pathologyCirdan
Personalised / Precision Medicine has revolutionized cancer treatment and, in parallel, is also deeply transforming the way we practice tissue pathology. The aim of this talk is to briefly review the status of molecular diagnostic tests applicable to tissues and cells, as well as the main technical and conceptual areas that, in my opinion, will be dictating the evolution of tissue pathology and its integration with the molecular era. These areas are, among others – a) digital pathology in the pipeline of therapeutic pathology; b) tissue-based NGS and its integration in routine diagnostics; c) the promise of liquid biopsy diagnostics and its necessary “partnership” with tissue molecular testing; d) Pathology IT, databases and bioinformatics; and e) the training of future tissue pathologists. In the process of this review, it may be apparent that a solid, integrated, morpho-molecular approach to pathology may serve our patients better.
Multimodality Molecular Imaging – An Overview With Special Focus on PET/CTApollo Hospitals
Imaging capabilities have evolved from those that provide anatomical pictures to those that capture functional information and, more recently, molecular information (nuclear medicine, PET, SPECT, PET/CT, SPECT/CT, MRS, contrast-enhanced ultrasound, fluorescence and bioluminescence imaging). Multimodality imaging has emerged as a technology that utilizes the strengths of different modalities and yields a hybrid imaging platform with benefits superior to those of any of its individual components, considered alone. Leading edge hybrid imaging (combining multiple, complementary imaging technologies such as PET and CT) offer unique opportunities to “view” the molecular biology of disease, and the use of this equipment is on the rise.
what will increase penile growth xp.
additive naftopidil remedy synergizes docetaxel-precipitated apoptosis in human prostate cancer cells. magazine of cancer research and scientific oncology one hundred forty four(1) : 89-98 (2018) interleukin-6 induces vegf secretion from prostate most cancers cells in a way independent of androgen receptor activation. the prostate 78(eleven) : 849-856 (2018) a hit protection of the bladder in a case of inflammatory myofibroblastic tumor with the diagnostic efficacy of alk/p80 immunohistochemistry and fish evaluation: case file and assessmen. What Increases Penile Growth Kit of the literature. urology case reviews 11 : 19-21 (2017) mixture treatment with naftopidil increases the efficacy of radiotherapy in computer-3 human prostate cancer cells. magazine of most cancers studies and clinical oncology 143(6) : 933-939 (2017) fibroblasts lengthen serum prostate-precise antigen decline after androgen deprivation therapy in prostate most cancers. laboratory investigation 96(three) 338-349, (2016), usefulness of tracking mobile-mediated immunity for predicting put up-kidney transplantation viral infection. transplantation proceedings forty six(2) 552-555(2014), radiofrequency ablation as opposed to radical nephrectomy: scientific results for stage t1b renal mobile carcinoma. radiology 270(1) 292-299 (2014), the usefulness of diffusion-weighted magnetic resonance imaging in bladder most cancers staging and purposeful evaluation. journal of cancer research and therapeutics 10(4) 878-882(2014), a case of igg4-positive plasma cellular-rich tubulointerstitial nephritis i. What Increases Penile Growth Kit a kidney allograft mimicking igg4-associated kidney disease. nephrology 19(s3) fifty two-fifty six(2014), a success remedy of non-invasive bladder tumour in a haemophilia a patient with excessive-responding inhibitors: a case report. haemophilia 20(6) e399–e401( 2014), activation of fgf2-fgfr signaling within the castrated mouse prostate stimulates the proliferation of basal epithelial cells. biol reprod. 2013 oct 4;89(4):eighty one. doi: 10.1095/biolreprod.112.107516 (2013), radiofrequency ablation versus radical nephrectomy: clinical consequences for degree t1b renal cellular carcinoma. radiology. 2013 aug 7. [Epub ahead of print] manserin as a novel histochemical neuroendocrine marker in prostate most cancers. urologic oncology 31(6) 787-795(2013), oral naftopidil suppresses human renal-cellular carcinoma via inducing g(1) mobile-cycle arrest in tumor and vascular endothelial cells. cancer prev res (phila). 2013 sep;6(9):1000-6. doi: 10.1158/1940-6207.capr-13-0095. epub 2013 jul 30. renal cell carcinoma: radiofrequency ablation with a multiple-electrode switching machine--a section ii medical have a look at. radiology. 2013 apr;267(1):285-92. doi: 10.1148/radiol.12121070. ep
Integrative Everything, Deep Learning and Streaming DataJoel Saltz
Workshop on Clusters, Clouds, and Data for Scientific Computing, September 6, 2018
The need to create to label information and segment regions in individual sensor data sources and to create synthesizes from multiple disparate data sources span many areas of science, biomedicine and technology. The rapid evolution in sensor technologies – from digital microscopes to UAVs drive requirements in this area. I will describe a variety of use cases, describe technical challenges as well as tools, algorithms and techniques developed by our group and collaborators.
Radiotherapy and chemotherapy aim at killing tumor cells or at least stopping their multiplication. Those therapies have strong limitations: first, their inherent toxicity is not limited to tumoral cells, but also affects healthy tissue; second, only the strongest and most resistant tumoral cells are able to survive, leading to increasingly aggressive tumors.
(October 12, 2021) Webinar: Clinical Field MRI As A Measurement Instrument fo...Scintica Instrumentation
Watch our webinar where Professor Marc-Andre Fortin presented about the 3D printing of hydrogels and hydrated substances that have been introduced in various fields of biomedical research including regenerative medicine, cosmetic surgery, orthopedics, and medical physics.
However, one of the main challenges faced by 3D printing and bioprinting is geometrical conformity. In this presentation, studies requiring hydrogel 3D printing in the fields of ophthalmology, regenerative medicine, and medical physics, were described. MRI scanning procedures were developed and optimized for these specific applications.
The presentation highlighted the potential role of MRI in the development of more accurate, more precise 3D-printed hydrogel objects.
Peter Hamilton on Next generation Imaging and Computer Vision in Pathology: p...Cirdan
Automated image analysis has had a long history but continues to grow with massive improvements in algorithms, speed, performance, and with emerging opportunities for high throughput tissue biomarker analysis and automated decision support for primary diagnostics. Of particular importance is the development of computer vision and image analysis for H&E stained samples. This talk will outline recent advances in automated tissue analysis for biomarker discovery and diagnostics and how adoption of digital pathology will drive the demand for quantitative imaging and decision support.
As an example, PathXL have developed TissueMark for the automated identification and analysis of tumour in lung, colon, breast and prostate cancer digital H&E slides. The conventional pathological estimation of % tumour nuclei in H&E samples shows gross variation between pathologists, undermining the quality of next generation sequencing, molecular testing and patient therapy and potential of false negative diagnoses. TissueMark uses a combination of pattern recognition, glandular analysis and nuclear segmentation to identify premaligant and invasive cancer patterns in H&E stained tissues and use this to assess tumour cell numbers and annotate samples for nucleic acid extraction and molecular profiling. Benchmark data was generated to validate TissueMark technology and showed concordance of automated data with manual counts, accelerating tumour markup and improving sample quality assessment. This represents an example of how automated imaging of tissue samples can be of immense value in quantitative tumour analysis for molecular diagnostics, thereby improving reliability in discovery and diagnostics.
This together with other examples in pathology research and practice will demonstrate that next generation tissue imaging technology in digital pathology could radically change how pathology is practiced.
Molecular imaging has revolutionized our perceptions of imaging. This high impact field is finding transformative applications in the understanding, detection, and treatment of nearly all diseases.
The field of molecular imaging is a an exciting fusion and integration of many different disciplines including molecular biology, chemistry and probe design, imaging technologies, visualization, and image analysis, that are focused on understanding, detecting, and treating oncological, neurological, cardiovascular, inflammatory, metabolic, and infectious diseases. Based on their strengths, different imaging modalities provide different but equally valuable information that can be integrated in advancing our understanding of these diseases.
As the era of ‘omics’ progresses towards personalized medicine, the field of molecular imaging is finding multiple uses in noninvasive characterization of the molecular features of diseases and their impact on function. In complex diseases such as cancer, with its tremendous genetic diversity, it is becoming increasingly important to develop molecularly-targeted treatment strategies that combine detection with treatment.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Manuel Salto-Tellez on Personalised medicine and the future of tissue pathologyCirdan
Personalised / Precision Medicine has revolutionized cancer treatment and, in parallel, is also deeply transforming the way we practice tissue pathology. The aim of this talk is to briefly review the status of molecular diagnostic tests applicable to tissues and cells, as well as the main technical and conceptual areas that, in my opinion, will be dictating the evolution of tissue pathology and its integration with the molecular era. These areas are, among others – a) digital pathology in the pipeline of therapeutic pathology; b) tissue-based NGS and its integration in routine diagnostics; c) the promise of liquid biopsy diagnostics and its necessary “partnership” with tissue molecular testing; d) Pathology IT, databases and bioinformatics; and e) the training of future tissue pathologists. In the process of this review, it may be apparent that a solid, integrated, morpho-molecular approach to pathology may serve our patients better.
Multimodality Molecular Imaging – An Overview With Special Focus on PET/CTApollo Hospitals
Imaging capabilities have evolved from those that provide anatomical pictures to those that capture functional information and, more recently, molecular information (nuclear medicine, PET, SPECT, PET/CT, SPECT/CT, MRS, contrast-enhanced ultrasound, fluorescence and bioluminescence imaging). Multimodality imaging has emerged as a technology that utilizes the strengths of different modalities and yields a hybrid imaging platform with benefits superior to those of any of its individual components, considered alone. Leading edge hybrid imaging (combining multiple, complementary imaging technologies such as PET and CT) offer unique opportunities to “view” the molecular biology of disease, and the use of this equipment is on the rise.
what will increase penile growth xp.
additive naftopidil remedy synergizes docetaxel-precipitated apoptosis in human prostate cancer cells. magazine of cancer research and scientific oncology one hundred forty four(1) : 89-98 (2018) interleukin-6 induces vegf secretion from prostate most cancers cells in a way independent of androgen receptor activation. the prostate 78(eleven) : 849-856 (2018) a hit protection of the bladder in a case of inflammatory myofibroblastic tumor with the diagnostic efficacy of alk/p80 immunohistochemistry and fish evaluation: case file and assessmen. What Increases Penile Growth Kit of the literature. urology case reviews 11 : 19-21 (2017) mixture treatment with naftopidil increases the efficacy of radiotherapy in computer-3 human prostate cancer cells. magazine of most cancers studies and clinical oncology 143(6) : 933-939 (2017) fibroblasts lengthen serum prostate-precise antigen decline after androgen deprivation therapy in prostate most cancers. laboratory investigation 96(three) 338-349, (2016), usefulness of tracking mobile-mediated immunity for predicting put up-kidney transplantation viral infection. transplantation proceedings forty six(2) 552-555(2014), radiofrequency ablation as opposed to radical nephrectomy: scientific results for stage t1b renal mobile carcinoma. radiology 270(1) 292-299 (2014), the usefulness of diffusion-weighted magnetic resonance imaging in bladder most cancers staging and purposeful evaluation. journal of cancer research and therapeutics 10(4) 878-882(2014), a case of igg4-positive plasma cellular-rich tubulointerstitial nephritis i. What Increases Penile Growth Kit a kidney allograft mimicking igg4-associated kidney disease. nephrology 19(s3) fifty two-fifty six(2014), a success remedy of non-invasive bladder tumour in a haemophilia a patient with excessive-responding inhibitors: a case report. haemophilia 20(6) e399–e401( 2014), activation of fgf2-fgfr signaling within the castrated mouse prostate stimulates the proliferation of basal epithelial cells. biol reprod. 2013 oct 4;89(4):eighty one. doi: 10.1095/biolreprod.112.107516 (2013), radiofrequency ablation versus radical nephrectomy: clinical consequences for degree t1b renal cellular carcinoma. radiology. 2013 aug 7. [Epub ahead of print] manserin as a novel histochemical neuroendocrine marker in prostate most cancers. urologic oncology 31(6) 787-795(2013), oral naftopidil suppresses human renal-cellular carcinoma via inducing g(1) mobile-cycle arrest in tumor and vascular endothelial cells. cancer prev res (phila). 2013 sep;6(9):1000-6. doi: 10.1158/1940-6207.capr-13-0095. epub 2013 jul 30. renal cell carcinoma: radiofrequency ablation with a multiple-electrode switching machine--a section ii medical have a look at. radiology. 2013 apr;267(1):285-92. doi: 10.1148/radiol.12121070. ep
Integrative Everything, Deep Learning and Streaming DataJoel Saltz
Workshop on Clusters, Clouds, and Data for Scientific Computing, September 6, 2018
The need to create to label information and segment regions in individual sensor data sources and to create synthesizes from multiple disparate data sources span many areas of science, biomedicine and technology. The rapid evolution in sensor technologies – from digital microscopes to UAVs drive requirements in this area. I will describe a variety of use cases, describe technical challenges as well as tools, algorithms and techniques developed by our group and collaborators.
Radiotherapy and chemotherapy aim at killing tumor cells or at least stopping their multiplication. Those therapies have strong limitations: first, their inherent toxicity is not limited to tumoral cells, but also affects healthy tissue; second, only the strongest and most resistant tumoral cells are able to survive, leading to increasingly aggressive tumors.
Tumor angiogenesis is currently one of the key focal points in biomedical research. It is based upon the hypothesis laid out by Judah Folkman in 1971 that neovasculature is needed to support the growth and metastasis of tumors, and thus anti-angiogenic treatment might be an effective way to cure cancer. Genentech’s anti-VEGF-A drug Avastin a great demonstration of this concept, generating more than $2.7 billion of sales in 2008.
This was one of the sessions on Feb 12th 2011 at the ProductCamp Vancouver. These slides where prepared to moderate a discussion on open innovation concepts and challenges
La consapevolezza di un bell’aspetto rafforza l’autostima, migliorando il rapporto con sé stessi e con gli altri sia nella sfera personale che in quella professionale.
Il servizio di consulenza d'immagine secondo Silk Gift Milan si articola sugli aspetti dell'abbigliamento, degli accessori, del makeup e dell'acconciatura, che meglio valorizzano la tua immagine in diversi momenti della tua giornata.
Analisi del colore:
Secondo una teoria scientifica, è possibile identificare in natura quattro raggruppamenti di colori, definiti convenzionalmente come le quattro stagioni (Autunno, Inverno, Primavera, Estate). Ogni persona, in base alle proprie caratteristiche somatiche, è riconducibile ad una stagione specifica. In base alla tua stagione, imparerai a scegliere i colori da indossare e il make-up e l’ hair style più appropriati per te.
This was one of the sessions on Feb 12th 2011 at the ProductCamp Vancouver. These slides where prepared to moderate a discussion on open innovation concepts and challenges
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Abdominal Aortic Aneurysm (AAA) is a serious and potentially fatal disease that is prevalent in the older population. Scientists are making use of animal models to study the progression of this disease and the effects of therapeutic interventions over longitudinal studies.
Study of Endometrial Volume and Vascularity by 3D Power Doppler Ultrasound in...Crimsonpublishers-IGRWH
Study of Endometrial Volume and Vascularity by 3D Power Doppler Ultrasound in Women with Perimenopausal Bleeding by Ahmed Sherif in Investigations in Gynecology Research & Womens Health
Application Brief: Tumor Microenvironment Imaging with Photoacoustic TechnologyFUJIFILM VisualSonics Inc.
Photoacoustics (PA) combines optical contrast with the high spatial resolution and deep tissue penetration offered by ultrasound. Such applications are especially beneficial for monitoring tumor development, measuring blood concentration changes within it, and quantifying networks of vasculature formation and carcinoma growth over time.
Application Brief: Tumor Microenvironment Imaging with Photoacoustic TechnologyFUJIFILM VisualSonics Inc.
Combining photoacoustic technology with high-resolution ultrasound projections offered by the Vevo 2100 system provides tremendous benefits for cancer screening. Researchers can now benefit from the combined high-resolution ultrasound and optical contrast ability of the Vevo® LAZR photoacoustic imaging system to achieve clear, deep, images in 2D and 3D for optimal in vivo visualization and quantification of internal anatomy, tumor tissue, and hemodynamics.
The study of disease transmission
By and large, the frequency of disease is higher in men than in ladies and higher in industrialized areas and countries.
Vevo 3100 - The ultimate preclinical imaging experience. The Vevo 3100 is a new and innovative platform created for the future of imaging. It combines ultra high frequency ultrasound imaging, quantification and education in a convenient all-in-one touchscreen platform.
White Paper: In vivo Fiberoptic Fluorescence Microscopy in freely behaving miceFUJIFILM VisualSonics Inc.
Fiberoptic fluorescence microscopy (FFM) employs optical fibers as small as 300 micrometers in diameter and offers the ability to image cellular and subcellular processes in deep brain structures including the Ventral Tegmental Area (VTA) and the substantia nigra (Sn).
Development and Validation of a Combined Photoacoustic Micro-Ultrasound Syste...FUJIFILM VisualSonics Inc.
Photoacoustic (PA) Imaging can estimate the spatial distribution of oxygen saturation (sO2) and total hemoglobin concentration (HbT) in blood, and be co-registered with B-Mode ultrasound images of the surrounding anatomy. This study will focus on the development of a PA imaging mode on a commercially available array based micro-ultrasound (μUS) system that is capable of creating such images.
Microdialysis is an integral part of preclinical research to determine extracellular fluid and blood concentrations of metabolites, hormones, drugs, etc, and is often used in quantifying the biochemistry of brain and peripheral tissues. However, it is a molecular-only technique and other imaging modalities are needed to provide the researcher with functional and anatomical information of the animal in vivo.
In this application, Cellvizio was used to study the neuronal degeneration and regeneration processes in live, anaesthetized, adult Thy1-YFP transgenic mice.
VisualSonics has introduced a revolutionary micro-ultrasound and photoacoustic imaging system that allows researchers to collect a plethora of important data over the lifespan of animals, thereby significantly reducing the number of animals needed.
Ischemia - or the lack of blood supply to a tissue - and subsequent reperfusion induces physiological and biochemical changes in the affected tissue and is an important area of study since the damage that occurs as a result is clinically important in diabetes and stroke.
Pulse oximetry has been used for diagnosing cyanosis, dyspnea and tachypnea (Schutz and Saunders., 2001). However, it is limited by accuracy-inhibiting factors, such as; decreased peripheral pulses, body temperature and blood pressure.
Application Brief: Imaging Oxygen Saturation with Photoacoustic Technology
Application Brief - Cancer Angiogenesis
1. Application Brief – Cancer Angiogenesis
Executive Summary
Tumor angiogenesis is currently one of the key focal points in biomedical research. It is based upon
the hypothesis laid out by Judah Folkman in 1971 that neovasculature is needed to support the
growth and metastasis of tumors, and thus anti-angiogenic treatment might be an effective way to
cure cancer. Genentech’s anti-VEGF-A drug Avastin a great demonstration of this concept,
generating more than $2.7 billion of sales in 2008.
However, cancer angiogenesis research in animal models has long been hindered by the lack of a
fast, portable, high resolution, research and animal focused imaging system that can visualize 3D
tumor volume, neoangiogenesis, and blood perfusion in vivo, in real time, and most importantly,
non-invasively. Indeed, it took 33 years after Folkman’s hypothesis for the first anti-angiogenic
treatment to be approved by the FDA. In order to ameliorate this problem, VisualSonics has
introduced a revolutionary micro-ultrasound system that allows researchers to collect a plethora of
important data over the lifespan of animals, thereby significantly reducing the number of animals
needed. 3D tumor volume, tumor vascularity, and tissue perfusion can be quickly quantified, while
MicroMarkerTM contrast agents allow the visualization of capillaries, and also to track expression of
endothelial cell markers such as VEGF.
Numerous satisfied cancer researchers using Vevo® micro-ultrasound systems, from institutions
such as Vanderbilt, Stanford, and Toronto are publishing articles in leading journals such as
Science, Clinical Cancer Research, PNAS, and Cancer Research. This is a testament of the power
and versatility of high resolution ultrasound.
3D Volume Quantification
Application Brief: Cancer Angiogenesis ver1.0 1
2. Background on Cancer Angiogenesis
The field of cancer angiogenesis was established by Folkman in his novel hypothesis published in
1971,1 in which he suggested that tumor growth is angiogenesis dependant. If angiogenesis can be
stopped or prevented from occurring, then tumors would no longer be able to proliferate and harm
its host. Over the next few decades, new research findings have further advanced this field. For
example, it’s been found that in situ carcinomas may exist for years without switching to the
angiogenic phenotype. This neoangiogenesis event is governed, at least in part, by the balance of
positive and negative angiogenic factors, such as VEGF, aFGF, bFGF, angiogenin, etc.2
Armed with this information, scientists began earnestly to look for the silver-bullet: anti-angiogenic
compounds that have low toxicity, low drug resistance, and high efficacy.2 However, it was 33
years later before the first anti-angiogenic therapy, bevacizumab, was approved by the FDA.3
Specifically, bevacizumab is a humanized antibody against vascular endothelial growth factor A
(VEGF-A). Since then, other anti-angiogenic compounds have been approved around the world,5
but it has been clear that the survival benefits offered by these expensive therapies were modest
at best.3 In order to further understand the mechanisms behind these drugs and to improve
therapy, new theories have been postulated, including the theory of transient “tissue
6
normalization” caused by these drugs.
In today’s research, time is of the essence. To test these novel hypotheses and discover new drugs
that will hopefully be on the market before three more decades, scientists need access to imaging
modalities that grant them the possibility of visualizing tumor angiogenesis in vivo, non-invasively,
and in real-time. Obviously, histology and dissection do not fill these criteria. MRI, PET, and SPECT,
while each having unique benefits, still suffer from problems such as radiation, high
setup/maintenance costs, and lack of vasculature-confined contrast agents. This is where high
frequency ultra-sound comes in.
Tumor Angiogenesis Quantification
Application Brief: Cancer Angiogenesis ver1.0 2
3. Micro-Ultrasound in Cancer Angiogenesis Research
Micro-ultrasound using high frequency probes and intravenous contrast agents has been regarded
as an attractive technique for accessing angiogenic activity and monitoring anti-angiogenic
therapy.7 Most research in this area is done using mice, because of their wide availability, variety
of strains, and ease of handling. Micro-ultrasound is especially suitable to study mice as they are
the perfect size to take advantage of the maximum resolution Vevo systems offer.
For example, Olive et al. recently reported their findings in Science of using the Vevo high
resolution system to image normal and diseased tissue in a mouse model of pancreatic cancer.8 In
addition to measuring 3D tumor volume twice weekly, the researchers were able to make use of
MicroMarker microbubbles to visualize tumor perfusion. With this tool, they were able to determine
that KPC (Kip1 ubiquitylation-promoting complex) tumors were poorly perfused within the tumor
parenchyma, despite being surrounded by well-perfused tissue.8 The group also used micro-
ultrasound to detect changes in the tumor with injection of gemcitabine, which caused transient
response in the tumor correlating to high levels of apoptosis8.
Palmowski et al. recently published in Cancer Research their findings of using high-frequency
volumetric Power Doppler ultrasound to capture flow-dependant signals and assess antiangiogenic
effects in a murine A431 model.9 The researchers used the Vevo 770 system to visualize the effects
of administration of SU11248 on tumor volumes and vascularity over a period of 9 days.9 In
addition, the researchers made use of a novel technique: destruction of microbubbles by high-
mechanical index ultrasound sonoporation with the Vevo, to allow for a superior visualization of
early antiangiogenic effects.
Many other researchers in recent years have also been using Vevo systems as an easily accessible,
applicable, fast, and superior way to image tumor volume and angiogenesis. For a complete list of
publications, please refer to document titled Bibliography of Recent Cancer Research Papers
featuring Vevo Systems.
Tumor Blood Flow
Application Brief: Cancer Angiogenesis ver1.0 3
4. VisualSonics’ Value Proposition
Cancer research and angiogenesis visualization has traditionally been associated with imaging
modalities such as MRI, CT, PET, and SPECT. However, despite their various strengths, many of
these systems suffer from significant drawbacks, including significant costs, in addition with
complicated operating needs such as radioisotopes. Furthermore, none of the above imaging
modalities is real-time per se, compared with micro-ultrasound which can capture images at up to
300 frames per second to study blood flow, perfusion, and important cardiotoxicity parameters.
With Vevo systems, researchers now have access to a tool to visualize small animals in real time
and in vivo. In fact, it has been demonstrated by Loveless et al. that micro-ultrasound produces
images eclipsing MRI resolution, and that the two imaging systems can be combined to validate
each other’s results.10
Below is a summary of the unique value proposition VisualSonics delivers to researchers with the
Vevo micro ultrasound systems:
1. Non-invasive, in vivo, real-time imaging for processes that happen over a period of time,
such as angiogenesis and tumor volume changes.
2. Screening modality for early tumor detection (>1x10-4 mm3). This allows quick sorting of
study animals to optimize homogeneity of test subjects.
3. Sophisticated quantification of tumor volumes in 2D and 3D. Together with stunning clarity
of down to 30 μm, the researcher is given maximum flexibility in choosing from a wide
variety of tumor models in small animals.
4. Observation of capillary formation and flow in neoangiogenesis, together with information
on flow velocity and tumor perfusion. This gives the cancer researcher a powerful tool to
examine therapeutic effects of drugs on angiogenesis over a longitudinal study.
5. Targeted biomarker molecular imaging with antibody-bound contrast agents. (VEGFR,
integrins, VE-Cadherin, etc.) The unique property of these contrast agents to stay in the
vasculature provides unparalleled power for angiogenesis biomarker research.
6. Guidance of micro-injections of stem cells, drugs, interstitial pressure probes etc. into
tumors or vasculature, without need for invasive surgery.
7. Detection and quantification of cardiotoxicity in response to cancer therapy. The
incomparable image acquisition speed and huge variety of software analysis tools allows for
elaborate assessment of cardiac function.
8. Dedicated animal platform to monitor ECG, heart rate, body temperature, and respiration
rates. The researcher is able to keep track of different parameters of the animal physiology
Application Brief: Cancer Angiogenesis ver1.0 4
5. in real-time throughout the imaging session, and to maintain the animal under ideal
conditions. Together with our specially designed anesthesia system, this also allows
researchers to spend minimal time on preparatory work and thus optimize throughput.
For a full list of cancer applications with the Vevo, together with examples from literature, please
consult White Paper: High Resolution Micro-Ultrasound for Small Animal Cancer Imaging.
Vevo 2100 Micro-Ultrasound Imaging System
Application Brief: Cancer Angiogenesis ver1.0 5
6. References
1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med
1995;1(1):27-31.
3. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an
anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
5. Kerbel R. Molecular origins of cancer: tumor angiogenesis. N Engl J Med
2008;358(19):2039-49.
6. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic
therapy. Science 2006;307:58-62.
7. Cristofanilli M, Charnsangavej C, Nortobagyi GN. Angiogenesis modulation in cancer
research: novel clinical approaches. Nat Rev Drug Discov 2002;1:415-26.
8. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition
of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science 2009 Jun 12;324(5933):1457-61.
9. Palmowski M, Huppert J, Hauff P, Reinhardt M, Schreiner K, Socher MA, et al. Vessel
fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional
high-frequency doppler ultrasound respond differently to antiangiogenic treatment. Cancer
Res 2008 Sep 1;68(17):7042-9.
10. Loveless ME, Whisenant JG, Wilson K, Lyshchik A, Sinha TK, Gore JC, et al. Coregistration of
ultrasonography and magnetic resonance imaging with a preliminary investigation of the
spatial colocalization of vascular endothelial growth factor receptor 2 expression and tumor
perfusion in a murine tumor model. Mol Imaging 2009;8(4):187-98.
Application Brief: Cancer Angiogenesis ver1.0 6